Anti-tumour necrosis factor (anti-TNF) biologics such as infliximab and adalimumab are effective in the induction and maintenance of remission in IBD, with primary response rates of 40–70% [3,4,5,6,7,8]. The gene discussed is TNF; the disease is inflammatory bowel disease.